Trial Profile
A Phase II trial of TSR-042 versus standard of care in first line NSCLC
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs Dostarlimab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 08 Aug 2018 New trial record
- 02 Aug 2018 According to a TESARO media release, the company expects to initiate this trial in early 2019.